| Ticker Details |
Mersana Therapeutics, Inc.
Mersana Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing antibody drug conjugates, or ADCs, that offer a clinically meaningful benefit for cancer patients with significant unmet need.
|
| IPO Date: |
June 28, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$145.36M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.30 | 3.87%
|
| Avg Daily Range (30 D): |
$0.20 | 0.69%
|
| Avg Daily Range (90 D): |
$0.27 | 1.99%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.14M |
| Avg Daily Volume (30 D): |
M |
| Avg Daily Volume (90 D): |
.08M |
| Trade Size |
| Avg Trade Size (Sh.): |
22 |
| Avg Trade Size (Sh.) (30 D): |
210 |
| Avg Trade Size (Sh.) (90 D): |
70 |
| Institutional Trades |
| Total Institutional Trades: |
1,423 |
| Avg Institutional Trade: |
$1.69M |
| Avg Institutional Trade (30 D): |
$3.51M |
| Avg Institutional Trade (90 D): |
$1.8M |
| Avg Institutional Trade Volume: |
.24M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.72M |
| Avg Closing Trade (30 D): |
$8.07M |
| Avg Closing Trade (90 D): |
$4.58M |
| Avg Closing Volume: |
227.67K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$-1.51
|
|
|
Diluted EPS
|
|
$-1.51
|
|
|
Revenue
|
|
$11.01M
|
|
|
Gross Profit
|
|
|
|
|
Net Income / Loss
|
|
$-7.55M
|
$-24.3M
|
|
Operating Income / Loss
|
|
$-7.67M
|
|
|
Cost of Revenue
|
|
|
|
|
Net Cash Flow
|
|
|
|
|
PE Ratio
|
|
|
|
|
|
|
